Сторінка 1 від 70 результати
FIELD OF THE INVENTION
The present invention relates generally to the field of cancer therapeutics. More specifically, the present invention relates to the use of ketone thyroxine analogues having no significant hormonal activity, particularly 1-[3,5-diiodo-4-(4'-methoxyphenoxy)-phenyl]-ethanone
FIELD OF THE INVENTION
The present invention relates to compositions and methods for treatment of proliferative disease. In specific aspects, the present invention relates to compositions including (1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1-,4a-dimethyl-7-(1-methyleth-
FIELD OF THE INVENTION
The present invention relates to alkyl ketone compounds effective for treating tumor cells and particularly effective to induce apoptosis in leukemia cells, breast cancer cells, prostate cancer cells, and brain cancer cells.
BACKGROUND OF THE INVENTION
Cancer is a major
TECHNICAL FIELD
The present invention relates to ketone derivatives and an agent having the ketone derivatives or pharmaceutically acceptable salts thereof as an active ingredient, and in particular, relates to a hematopoietic agent.
BACKGROUND ART
Ketone derivatives include lactones and lactams.
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 2',4'-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds (collectively referred to herein as "DCBP compounds"). The present invention also pertains to
BACKGROUND
Pancreatic cancer is the fifth leading cause of cancer death in the United States. It is more common among men, and men between the ages of 60 and 70 are most at risk. Pancreatic cancer usually begins in the ducts of the pancreas when abnormal cells within the pancreas grow out of control
BACKGROUND
Pancreatic cancer is the fifth leading cause of cancer death in the United States. It is more common among men, and men between the ages of 60 and 70 are most at risk. Pancreatic cancer usually begins in the ducts of the pancreas when abnormal cells within the pancreas grow out of control
BACKGROUND
Pancreatic cancer is the fifth leading cause of cancer death in the United States. It is more common among men, and men between the ages of 60 and 70 are most at risk. Pancreatic cancer usually begins in the ducts of the pancreas when abnormal cells within the pancreas grow out of control
BACKGROUND
Pancreatic cancer is the fifth leading cause of cancer death in the United States. It is more common among men, and men between the ages of 60 and 70 are most at risk. Pancreatic cancer usually begins in the ducts of the pancreas when abnormal cells within the pancreas grow out of control
BACKGROUND
Cancer is a leading cause of death in the United States. For example, cervical cancer often has a poor prognosis, even when diagnosed early, and signs and symptoms may not appear until the cancer is quite advanced and complete surgical removal is not possible.
Conventional treatment
BACKGROUND
Cancer is a leading cause of death in the United States. For example, cervical cancer often has a poor prognosis, even when diagnosed early, and signs and symptoms may not appear until the cancer is quite advanced and complete surgical removal is not possible.
Conventional treatment
BACKGROUND OF THE INVENTION
Field of the Invention
This disclosure relates to dipeptide and tripeptide epoxy ketone protease inhibitors including methods of making and using the same.
Description of Related Technology
In eukaryotes, protein degradation is predominately mediated through the ubiquitin
FIELD OF THE INVENTION
This invention relates to selective peptidyl inhibitors of cancer procoagulant (CP), a protein elaborated by malignant, but not normal, animal and human cells, and to the use of these selective peptidyl inhibitors in cancer therapy and in CP removal from blood.
BACKGROUND OF
FIELD OF THE INVENTION
This invention relates to methods of treating cancers and oncogenic diseases. Specifically, the invention provides a novel method of targeting cancerous tissues using hyperbaric oxygen and ketone-based metabolic therapy.
BACKGROUND OF THE INVENTION
Despite decades of intensive
BACKGROUND
The complement system is a part of the innate immune system which does not adapt to changes over the course of the host's life, but is recruited and used by the adaptive immune system. For example, it assists, or complements, the ability of antibodies and phagocytic cells to clear